Adicet
formerly Adicet BioIPOGamma Delta T cells | Off the-shelf T cell therapy
Redwood City, United States · Founded 2014 · $131.0M raised
- Headquarters
- Redwood City, California
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Total Funding
- $131.0M
- Last Round
- $80.0M Series BOct 2019
- Rounds
- 2
About
Adicet Bio is a clinical-stage biotech developing off-the-shelf allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Founded in 2014 and headquartered in Redwood City, CA, with offices in Boston and Shanghai.
Summary
Adicet is a Biotech company based in Redwood City, United States, founded in 2014. It has raised $131.0M in total across 2 rounds, most recently a $80.0M Series B round in Oct 2019. Investors include OrbiMed, Novartis Venture Fund and Pontifax.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2019
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...